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Vitamin D (VD) is a secosteroid hormone that is mainly synthesized in the skin upon exposure to UVB radiation. VD is
widely known for its role in calcium metabolism; however, multiple endocrine, paracrine and autocrine functions of VD
have been described, including a prominent role on carcinogenesis. In recent years, multiple associations between VD
deficiency and different types of cancer have been described, supported by evidence of anti-proliferative, anti-angiogenic,
pro-apoptotic, cell-differentiating and anti-invasive effects of this hormone. An immunomodulatory role of VD associated to
cancer microenvironment has also been suggested. Regarding skin cancer, it has been shown that VD inhibits tumor
development in basal cell carcinoma, squamous cell carcinoma, and melanoma in vitro. Some studies have suggested that
lower VD levels may be a risk factor for skin cancer, while others have shown the opposite; there is also preliminary
evidence on the role of VD supplementation for the prevention of melanoma in vivo. In this review, we explore the
mechanisms of VD effects on carcinogenesis and the available scientific evidence of the interplay between VD and the
genesis of both non-melanoma and melanoma skin cancer.
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Vitamin D (VD) is a secosteroid hormone that is mainly
synthesized in the skin from cholesterol precursors upon
exposure to UVB radiation or to a lesser degree acquired
from dietary sources. Widely known for its role in
calcium metabolism, multiple other endocrine, paracrine
and autocrine functions of VD have been described [1],
with increasing emphasis on the role in modulating the
innate and acquired immunity.
In recent years, a plethora of articles have been published
associating lower VD levels with the development of
different cancer types (Table 1); additionally, a lower survival
rate has been shown in patients with lower VD levels in
some studies [2, 3]. Unfortunately, only few reports have
found an impact of VD supplementation on the subsequent
risk of cancer. The role of VD on the occurrence and prog-
nosis of skin cancer has increasingly been studied, but
current evidence is still controversial.* Correspondence: sgonzale@med.puc.cl
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ging role of VD as potential factor for carcinogenesis,
mainly focusing on its role in melanoma and non-
melanoma skin cancer.Vitamin D metabolism
VD is mainly synthesized in the skin (90%) and to a lesser
extent obtained from dietary sources (10%) [1]. After ex-
posure to UVB radiation (λ280-320 nm) a photochemical
reaction converts 7-dehydrocholesterol to vitamin D3
(VD3) by epidermal basal keratinocytes [4]. VD3, as well
as VD2 obtained from diet, is released to the extracellular
space and then to the bloodstream, where it is captured by
VD binding protein (DBP) [4]. Subsequently, VD is hydro-
xylyzed in hepatocytes where the hydroxylase CYP2R1
produces 25(OH)D, the major and more stable metabolite
of VD commonly used to evaluate VD plasmatic status
[5]. Finally, in the kidney 25(OH)D is converted to the ac-
tive form 1,25(OH) 2D3 (calcitriol) by CYP27B1, which is
the active form of VD. Due to its short half-life of the lat-
ter, it is not routinely measured [6]. This two enzymatic
processes can also be locally made in the epidermis by
keratinocytes and melanocytes [7].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 2 Vitamin D associated functions
Function Effect Reference
Metabolism • Calcium Homeostasis
• Anabolic effect in muscle
metabolism
• VD deficiency associated





Immunologic Effect on T lymphocytes:
• stimulation TH2 and T
regulatory cells
• reduces TH1 and TH17
response






• decreases IL-17, IL-21
• stimulates cathelicidin
and in β-defensin in
macrophages












Low VD level associated with Lupus,
asthma, atopic dermatitis, rheumatoid
arthritis, inflammatory bowel disease,








Neuroprotective VD is present in substantia nigra and
hypothalamus
VD deficiency associated with Alzheimer’s
disease
[13]
Pregnancy Low VD levels during pregnancy
associated with pre-eclampsia, gestational
diabetes and small for gestational age
infants.
[5]
Table 1 Carcinogenic mechanism associated with vitamin D in




cell-differentiating and anti-invasive effects in
tumor cells
[29–31]
Higher levels of VD are correlated with decreased
risk of breast, colon, renal, hepatic and
tobacco-related cancers.
[3, 33–37]
Associated to a decrease in the risk of specific
cancer overall survival in breast, colon, hepatic,
and bladder carcinomas
[3]
Vitamin D supplementation reduces the risk
of cancer in postmenopausal women
[40]
Skin cancer:
Reduction in melanoma cells proliferation in vitro. [52]
Induces melanoma cells differentiation, inhibits
angiogenesis and invasion
[29]
Activates DNA repair enzymes after UV irradiation
of melanocytes
[45, 54]
Inhibits sonic hedgehog pathway in basal
cell carcinoma
[46]
Inhibits squamous cell carcinoma cells [49]
Role in the expression of E-cadherin and
B-catenin in basal cell carcinoma, squamous
cell carcinoma and in melanoma.
[29, 43, 44]
Arrests tumor cell cycle in G1/S, inhibiting
cyclin D1 and upregulating p27 and p21.
[53]
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discovered, in which VD3 is directly metabolized by the
hydroxylase CYP11A1 producing a number of different
derivatives from VD3, some of which can be metabolized
by CYP27B, producing different but active metabolites,
mainly 20(OH) D3. This new pathway has been found
on the placenta, adrenal glands and epidermal keratino-
cytes, and may play an important role in carcinogenesis
due to antiproliferative and prodifferentiation effects [8].
Vitamin D levels
VD serum levels vary widely by latitude, season, age,
body mass index, use of sunblock and skin pigmentation
(as melanin absorbs UVB radiation inhibiting VD3 syn-
thesis in the skin) [9, 10]. Despite VD3 can be obtained
from diet (about 10% of VD), its metabolic process is
not as efficient as skin VD3 synthesis (90% of VD levels):
[11] VD3 from skin lasts 2-3 times longer in the serum
than dietary VD3 [12]. Moreover, dietary VD3 binds only
in a 60% to DBP while the remainder is rapidly cleared;
in contrast up to 100% of skin synthetized VD3 can be
bound to DBP. In addition, the rest of dietary VD3 is
eliminated rapidly through urine [11].
The mechanism of obtaining VD3 from sunlight is also
efficient: A 15 min sunlight exposure of arms and legs in asunny day is sufficient and produces 2000-4000 UI of VD
for fair-skinned Central Europeans [13] (this estimates
vary according to season, latitude and ethnics) [1, 14, 15].
Vitamin D effects
Once VD is synthesized it has two main actions: First, it
binds to the nuclear VD receptor (VDR), which then
binds to its co-receptor RXR and form a transcription
factor which activates the expression of more than 3000
genes [16]. Second, in the cell membrane VD can bind
to a binding protein (PDIA3), where it regulates intracel-
lular calcium concentration [16, 17]. The VDR is an ubi-
quitous receptor that is expressed by most bodily tissues
including intestine, skeletal system, bone marrow, breast,
prostate, brain, muscle, immune cells, keratinocytes, me-
lanocytes and neoplastic cells [16, 18]. In the following
sections, we will focus on VD's immunologic and anti-
carcinogenic effects (Table 2).
Del Puerto et al. Applied Cancer Research  (2016) 36:5 Page 3 of 8Immunologic effect of VD
VD has multiple immunologic effects that result in the
ability to promote protective immunity and maintain tol-
erance [9]. Multiple cross-sectional and epidemiological
studies have shown that low levels of VD are associated
with an increased risk of respiratory tract infections, tu-
berculosis, bacterial vaginosis and even HIV infection,
among others [19–22].
It is also well studied that low VD levels are associated
with higher incidence and severity of several autoimmune
diseases such as lupus, rheumatoid arthritis, multiple
sclerosis, diabetes and inflammatory bowel disease [9]. VD
plays a key role in the innate immune system antimicro-
bial response. VD directly enhances the transcription of
cathelicidin and β-defensin, antimicrobial peptides that ac-
tively participate in immunity of skin [23].
VD also acts in B cells (inhibiting proliferation and dif-
ferentiation of B cells and immunoglobulin secretion);
[24] T cells (inhibiting proliferation, and hampering T
cell effector responses and increasing T regulatory cells)
[9, 25, 26], thus acting in the adaptive immune system,
suppressing inflammatory cytokines (IL-17, IL-21) and
increasing regulatory cytokine IL-10 [9]. However, ef-
fects of VD on the adaptive immune system are com-
plex, as it also causes increases in Th1 immunity by
stimulating the transcription of IFNγ, thus having anti-
microbial effects. Finally, VD acts in monocytes and den-
dritic cells suppressing production of important
inflammatory cytokines (IL-1, IL-6, IL-8, IL-12 and
TNFα) in the former and inhibiting maturation and dif-
ferentiation in the latter [27, 28].
Role of VD in carcinogenesis modulation
The multiple associations between VD deficiency and
higher incidence and mortality due to cancer are of in-
creasing concern, supported by the anti-proliferative,
anti-angiogenic, pro-apoptotic, cell-differentiating and
anti-invasive effects of this hormone [29–31]. An associ-
ation has been suggested between low serum VD levels
and increased incidence of cancer and mortality, thus
outstanding a possible prophylactic role of VD, among
many others [29, 32].
Several prospective cohort studies have demonstrated
that higher levels of VD are correlated with decreased
risk of diagnosis of breast [33], colon [34], renal [35],
hepatic [36] and tobacco-related cancers [3, 37]. Low
VD serum levels also decrease specific cancer overall
survival in breast, colon, hepatic, and bladder carcin-
omas [3]. However, when adjusting for other prognostic
criteria, the association disappeared [3]. Recent studies
show that patients with colon cancer and high levels of
VD have lower risk of death irrespective of tumor stage
[38]. In hepatic carcinoma, a prospective study demon-
strated that low VD serum levels correlated with worsecirrhosis level, worse tumor stage and mortality risk
[39]. Finally, the WHO in postmenopausal women dem-
onstrated that VD and calcium supplementation reduced
the risk of all cancers [40]. However new prospective co-
hort studies with post diagnostic VD supplementation or
high baseline VD serum levels, have failed in showing
improvement of all-cause or disease-specific mortality in
colon, breast or prostate cancer patients [3, 41]. There-
fore, the role of VD as a prophylactic therapy in multiple
cancers is still a matter of debate; despite multiple stud-
ies showing preliminary evidence of VD as a risk factor
for the carcinogenesis and survival in cancer patients.
The role of DBP in cancer is a new focus of research.
A recent meta-analysis found a borderline but not sig-
nificant association between high levels of DBP and de-
creased cancer risk (OR 0,57 95%CI 0,57-1) [42]. No
studies on melanoma or skin cancer have been con-
ducted to evaluate the role of DBP in this population.
Vitamin D and skin cancer
VD immunologic and carcinogenic role in skin cancer is
a current point of research and may lead to important
changes in management strategies of skin cancers [29].
Keratinocytes produce VD, but can also synthesize
locally the active 1,25(OH) 2D form that acts in a auto-
crine and paracrine fashion. Skin VD synthesis is regu-
lated according to serum calcitriol levels [29]. VD
synthesis also varies by the degree of keratinocyte differ-
entiation. Moreover, keratinocytes also express VDR,
therefore they respond to calcitriol, which is known as
one of the most potent regulator of epidermal differenti-
ation. Other important function of VD is its capacity to
induce formation of intercellular junctions by Protein
kinase C (PKC) activation [29, 43]. It has been shown
that intracellular junctions are closely associated with
carcinogenesis, tumor progression and metastasis [29].
In fact, the expression of E-cadherin and B-catenin -im-
portant proteins of the intracellular junctions- are de-
creased in skin tumors: basal cell carcinoma (BCC),
squamous cell carcinoma (SCC) and in melanoma [29,
43, 44]. Another role that has been postulated of VD in
the skin is its capacity to prevent DNA-damage pro-
duced by UVB radiation [45].
It has been shown that VD inhibits Hedgehog signal-
ing pathway, suppressing tumor development in BCC
[46]. VDR-knockout mice have increased risk of BCC
development after exposure to a carcinogen [47], and
VD topical application inhibits BCC cell proliferation
in vivo and in vitro [48]. VD has also a role in SCC car-
cinogenesis, as it inhibits SCC cells growth in vivo and
in vitro [49]. Nested- case control studies in elderly men
have shown lower incidence of non-melanoma skin can-
cer (NMSC) in patients with highest serum levels of
25(OH) D [50] and higher levels of 25(OH) D were
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tases [11]. Despite these findings, studies to assess the
effect of VD supplementation or topical application in
BCC and SCC on humans are lacking.
VD and melanoma
Vitamin D effects in vitro and in vivo
Since the 1970’s there has been evidence of an effect of
VD in both melanocytes and melanoma cells. The first
finding was that VD stimulates melanogenesis as it pro-
motes tyrosinase synthesis [51]. Then in the 80’s, Col-
ston et al. [52] discovered that VDR was found in
melanoma cells, and that VD dramatically reduced cell
proliferation, in a dose-response manner. 1,25(OH)2D
causes arrest at the G1/S phase in tumor cell cycle,
mainly by inhibiting cyclin D1 and an upregulation of
p27 and p21 [53].
New findings were made showing that VD inhibits pro-
liferation, induces differentiation of melanoma cells, and
inhibits angiogenesis and invasion of melanoma cells [29]
with a protective antineoplastic effect. In fact, Gupta et al.
demonstrated that VD had an important role in the acti-
vation of the DNA repair mechanism after UV radiation,
both in keratinocytes and in melanoma cells [54].
The effect of VD in melanoma -as in other cancers-
depends of VD serum levels, DBP and the expression of
VDR in tissue and its polymorphisms. Studies analyzing
the association of genes coding for VD metabolizing en-
zymes (1 alpha-hydroxylase [CYP27B1] and 1,25(OH)
(2)D-24hydroxylase [CYP24A]), and DBP found no asso-
ciation between polymorphisms in these genes and mel-
anoma risk [55].
Melanoma and VDR polymorphisms
The VDR gene contains >1000 polymorphic sites [30].
The most studied in skin cancer are TaqI, BsmI, ApaI and
FokI [29, 56]. FokI and BsmI have been identified as high
risk alleles, and TaqI allele as a protective polymorphism
in melanoma [56]. In addition, the rs4516035 allele has
been reported to be a melanoma risk allele [57]. For BsmI
bb genotype, recent studies show a significant association
with frequency of melanoma, Breslow thickness, and even
with the risk of multiple primary melanomas [58].
Melanoma and VDR expression
Recent studies have shown a negative correlation between
immunohistochemical VDR expression and progression of
pigmented skin lesions, as VDR immunoreactivity was
strongest in normal skin > nevi >melanoma =metastasis,
for both nuclear and cytoplasmic expression [59]. How-
ever, the stain graduation was more pronounced in nu-
clear staining. The authors explain this alterations alluding
that for VD normal regulatory actions, both compart-
ments- nuclear and cytoplasmic- are relevant. However, asnuclear VDR expression and activation leads to activation
of target genes, the reduction of nuclear VDR expression
could contribute to the escape of melanoma cells from
homeostatic surveillance and growth control. Thus, reduc-
tion of nuclear VDR can induce some malignant features
of melanoma like unlimited replicative potential or the
ability to invade the dermis [56].
Furthermore, the same authors found that in melanoma,
VDR cytoplasmic and nuclear immunoreactivity was
lower in more aggressive nodular melanomas than in
superficial melanomas. Moreover, in the melanoma co-
hort, the nuclear and cytoplasmic VDR immunoreactivity
was associated with longer overall survival. A further
study by the same authors showed that VDR cytoplasmic
and nuclear expression in melanoma was inversely corre-
lated with Breslow thickness, Clark’s level and pTNM
AJCC staging [60] [57]. In addition, VDR expression was
decreased in melanomas with melanization and with ul-
ceration, but increased in those melanomas with high
tumor infiltrating lymphocytes (TIL) expression. This last
association could be explained because active lymphocytes
could express VD and that way induce an antineoplastic
activity [60]. Finally, VDR expression affected the survival
of patients with melanoma [60]. Our own unpublished
studies showed differential immunohistochemical expres-
sion of VDR in melanoma and nevi showing some differ-
ences with data reported in the literature (Fig. 1, panel).
Serum VD levels and melanoma
Since the last decade, multiple studies have tried to
evaluate the association between VD serum levels and
melanoma risk and/or prognosis. However, the results
have been contradictory. These discrepancies may be ex-
plained mainly because of multiple methodological dif-
ferences between studies: differences in adjustment of
VD by known confounding factors; differences in the
assay used to determine serum 25(OH)D levels; in the
cutoff point of normal-deficiency levels of VD between
studies; and differences in the time of the year (seasonal-
ity) and time from diagnosis of the melanoma when VD
serum levels where obtained, as some studies used
25(OH)D levels obtained even years after diagnosis of
melanoma (and could reflect the increased sun aware-
ness and protection after melanoma diagnosis).
In an effort to determine the real role of VD in melan-
oma pathogenesis, Caini et al. [61] made a meta-analysis
and analyzed the effect of 25(OH)D baseline serum
levels and the risk of melanoma genesis and of melan-
oma prognostic factors. They included 4 studies (392
melanoma cases), and found a borderline trend (though
not significant) between lower 25(OH)D and melanoma
risk. However, they did found that lower VD serum
levels were inversely correlated with melanoma
thickness.
Fig. 1 VDR immunohistochemical expression in melanoma and dermal nevus. a cytoplasmic and nuclear staining for VDR in dermal nevus, AEC,
400x; b negative VDR staining in melanoma in situ, AEC, 400x; c positive VDR nuclear staining in melanoma in situ, AEC, 400x; d positive VDR
nuclear staining in invasive melanoma, AEC, 400x
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levels and melanoma. Firstly, in their revision of the
Leeds Melanoma Cohort with 2182 patients followed for
7 years, Newton-Bishop et al. [62] analyzed the relation-
ship between known systemic markers of inflammation
(smoking, body mass index (BMI), low 25(OH)D serum
levels, and use of NSAIDs) with melanoma risk with
tumor ulceration and melanoma specific survival (MSS).
They found that deficient VD serum levels and smoking
were significantly associated with ulceration. When
multivariate analysis was made (adjusted by sex, age,
tumor location and Breslow thickness) deficient
25(OH)D serum levels (<20 mmol/L vs 20-60nmol/L =
HR 1,79; p = 0,009) and smoking duration significantly
decreased MSS. The authors suggested, based on their
results, correction of VD deficiency and smoking cessa-
tion might be of benefit for melanoma prognosis.
A cross-sectional Australian study with 100 patients
with recently diagnosed melanoma and VD levels ob-
tained at the moment of diagnosis, evaluated baseline
25(OH)D levels and melanoma prognostic factors. After
a multivariate analysis adjusted for confounding factors,
they found a significant association between VD defi-
ciency (defined as <50mmol/L by the Australian Health
survey) and Breslow thickness, a known factor of poorer
prognosis. In fact, they found a four-fold increase in the
odds of higher Breslow thickness (>0,75 mm) inassociation with low VD levels [63]. There was no asso-
ciation of 25(OH)D levels and Clark level or mitotic
activity.
Saiag et al. [3] reported a prospective-cohort study
with 1171 patients with melanoma followed for a mean
of 4.5 years, and studied VD serum levels at diagnosis
and during follow-up, in order to see if increased VD
levels during follow-up improved prognosis. After ad-
justment of 25(OH)D levels (by age, sex, BMI, and
month of blood drawn), 25(OH)D baseline levels were
significantly inversely correlated with poor prognostic
factors such as AJCC stage, Breslow’s thickness, and ul-
ceration. When evaluating 25(OH)D baseline levels ad-
justed by prognostic factors (AJCC staging) the
associations with melanoma relapse or prognosis disap-
peared, suggesting that VD levels were not an independ-
ent prognostic marker of melanoma. Then, they
analyzed the data of 856 patients that had at least two
values of VD serum levels measured, allowing calcula-
tion of an annual trend of 25(OH)D variation levels. The
annual variation of 25(OH)D over time and prognosis
showed a U-shape in Kaplan Meier curve, meaning that
any change above or under 0.5 nmol/L per year was sig-
nificantly associated with worse prognosis. Authors
could explain the relationship between decreased annual
trend of 25(OH)D levels and worse prognosis, assuming
tumor inflammation and lower sun exposure as the main
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VD decreased prognosis.
Vitamin D supplementation and melanoma risk and
progression
There have been few studies evaluating the real useful-
ness of VD supplementation and how it may affect mel-
anoma progression. Most of them have been based in
cohorts that studied supplementation for other diseases
and therefore the VD dosage and the adjustment by con-
founding factors was not accurate.
Interestingly, some studies support VD supplementa-
tion to prevent melanoma genesis. A case control study
by Millen et al. [64] conducted in 503 patients and 565
controls, found a reduced risk of melanoma in patients
with dietary VD intake. However, VD exposure data
were collected after melanoma diagnosis, which make
the results susceptible to recall bias.
With the scarce evidence available to date, supplementa-
tion with VD is not currently supported. A small case con-
trol study with 165 melanoma patients and 209 controls
found no association between VD intake or supplementa-
tion and further melanoma risk [65]. In contrast, another
prospective study found an increased risk between cod-
liver oil consumption (600-1000 UI VD/teaspoon) and
melanoma risk among women, but not men [66].
The first important epidemiological study was re-
ported with indirect data obtained by questionnaires.
The Vitamins and Lifestyle Cohort prospective study in-
cluded 68,611 participants, who were assessed for VD
dietary intake and/or supplementation and its associ-
ation with melanoma risk [67]. Data was extracted
through a baseline questionnaire of the last decade VD
intake and/or supplementation. After a year of follow-
up, 455 incident melanomas were identified. They found
no association between VD supplementation and/or
dietary intake and melanoma risk. However, this study
did not measured serum VD levels nor adjusted results
by other confounding risk factors.
Another indirect evidence arises from the post-hoc
analysis of the WHI CaD trial [68], which included
36282 participants who were randomly assigned to re-
ceive Calcium 100mg - VD 400 UI/daily or placebo.
After a mean 7-year follow up by annual questionnaire
reporting of melanoma or NMSC, the analysis found no
association between VD supplementation and a reduced
risk of NMSC or melanoma. However, in the group of
women with previous history of NMSC (a known risk
factor for melanoma) [69] there was a 57% of fewer mel-
anomas in the group who received supplementation ver-
sus placebo (HR 0.43; p = 0.026). The authors postulated
that the probable main cause of lack of association be-
tween supplementation and reduced risk is that the sup-
plementation was inadequate, as it was lower than therecommended 600 UI/d by the Institute of Medicine
consensus statement, and as it only raises serum VD
levels by 4ng/ml, an inadequate dose to observe clinical
differences in skin cancer [68].
Consequently with these data and based in its recently
systematic reviews, the US Preventive Services Task
Force concluded that the current available data were in-
sufficient to recommend VD screening in clinical prac-
tice or to assess a benefit of supplemental VD intake for
the primary prevention of cancer [70].
There are ongoing clinical pilot trials evaluating VD
supplementation with VD and cancer risk [71], and a
specific placebo controlled pilot trial evaluating high
dose VD supplementation in patients with advanced
melanoma, evaluating safety of dosage and progression
free survival, with promising outcomes [72].
Conclusions and future directions
For many years dermatologists have recommended pa-
tients simply avoiding sun exposure pragmatically in order
to prevent the appearance of skin cancer. Recent evidence
suggests a much more complex issue than initially
thought and that carcinogenesis is not as simple as “more
sun exposure, more skin cancer”. As VD levels are mainly
regulated by sun exposure, it seems that as with any other
hormone, a delicate equilibrium governs over the presence
of pathology or a homeostatic healthy environment. More
studies are needed in order to give patients solid evidence
based recommendations of optimal 25(OH)D levels, VD
supplementation, and sun exposure.
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